The impact of targeted agents on TLN is yet uncertain, but some studies have suggested that cetuximab, a monoclonal antibody to epidermal growth factor receptor (EGFR), might confer relatively high risk of TLN when used concurrently with RT in both treatment-naïve and recurrent NPC patients (6, 7). The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.